Aclaris Therapeutics Q3 revenue beats analyst estimates
ACRS•Aclaris Therapeutics reported Q3 revenue of $1.48 million, above the $1.30 million analyst estimate, while its $18.51 million net loss was smaller than expected. The company said its cash is expected to fund operations through the first half of 2029.
1. Quarterly results
Aclaris Therapeutics’ Q3 revenue declined year over year to $1.48 million, beating the $1.30 million analyst estimate. Its net loss widened year over year to $18.51 million, but was smaller than analysts’ $23.68 million estimate.
2. Outlook and costs
The company expects its cash to fund operations through the first half of 2029. It expects to initiate a Phase 2b trial of modzatinib in lichen planus in Q4 2026 and reaffirmed its timeline for top-line results from the Phase 2 ADMIRATION trial of bosakitug in atopic dermatitis. Aclaris said higher research and development costs mainly reflected manufacturing and clinical expenses for ATI-052 in atopic dermatitis and asthma; lower revenue was mainly due to a Sun Pharma license-agreement sales milestone achieved in the prior year.
